• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: J. Michael Pearson     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatDukeUniversityAlumni, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingfoaf:Personpersondul:NaturalPersonEukaryotePersonHumanAnimalanimaleukaryotespeciesschema:Personyago:WikicatLivingPeopleyago:Alumnus109786338yago:CausalAgent100007347yago:Intellectual109621545yago:LivingThing100004258yago:Object100002684yago:Organism100004475yago:Person100007846yago:PhysicalEntity100001930yago:YagoLegalActoryago:YagoLegalActorGeoyago:Scholar110557854yago:Whole100003553yago:WikicatDukeUniversityAlumni New Facet based on Instances of this Class

J. Michael Pearson (born 1959) is a Canadian American pharmaceutical company executive. He is the former chairman and CEO of Valeant Pharmaceuticals International after being ousted in the aftermath of a report on pharmaceutical pricing published by Citron Research in April 2016. On April 27, 2016, Pearson, Bill Ackman and Howard Schiller appeared before the United States Senate Special Committee on Aging to answer concerns over the repercussions for patients and the health care system whom are affected by Valeant's business model.